Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLL1 | O43897 | 1/20 | 0.43 |
| ▸ | BMP1 | P13497 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | TLL2 | Q9Y6L7 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7387885 | 0.96 | TLL1 (0.42) | TLL1BMP1MMP12TLL2ALOX5 | |
| SCHEMBL7879226 | 0.87 | BMP1 (0.47) | TLL1BMP1MMP12TLL2ALOX5 | |
| SCHEMBL7876860 | 0.85 | BMP1 (0.40) | TLL1BMP1MMP12TLL2ALOX5 | |
| SCHEMBL7879214 | 0.84 | SLC1A3 (0.49) | TLL1BMP1MMP12TLL2CTSK | |
| SCHEMBL7868133 | 0.84 | TDP1 (0.45) | — | |
| SCHEMBL7873373 | 0.83 | LTB4R (0.44) | ALOX5LTB4RTRPA1 | |
| SCHEMBL7876532 | 0.82 | LTB4R (0.46) | ALOX5LTB4RTRPA1 | |
| SCHEMBL7902677 | 0.81 | GRIK1 (0.39) | TLL1BMP1MMP12TLL2ALOX5 | |
| SCHEMBL7902679 | 0.81 | GRIK1 (0.39) | TLL1BMP1MMP12TLL2ALOX5 | |
| SCHEMBL7876988 | 0.81 | SLC1A3 (0.41) | TLL1BMP1MMP12TLL2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6329400-B1 | INHIBITION OR ANTAGONISM OF MATRIX METALLOPROTEASES, AND/OR TUMOR NECROSIS FACTOR-ALPHA; EXTRACELLULAR MATRIX DEGRADATION, INHIBITION OF SHEDDING OF CELL SURFACE PROTEIN ECTODOMAINS AND CD23 PROTEOLYSIS | GLAXO WELLCOME INC. | 2001-12-11 | — | — | US | disclosed |